Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer

This article has no abstract
Epistemonikos ID: 42f65b7933317d67b5daf1f386a05d6dd7490f9c
First added on: Feb 28, 2025